Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017

胸腺瘤 胸腺癌 医学 入射(几何) 内科学 癌症登记处 癌症 胃肠病学 肿瘤科 病理 光学 物理
作者
Dong Wook Shin,Jong Ho Cho,Johyun Ha,Kyu‐Won Jung
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:17 (6): 827-837 被引量:19
标识
DOI:10.1016/j.jtho.2022.02.001
摘要

IntroductionTo report the trends in incidence and survival associated with thymic epithelial tumors (TETs) in Korea.MethodsData from 1999 to 2017 were obtained from the Korean Central Cancer Registry. Age-standardized incidence rates and average annual percentage changes (AAPCs) were calculated. Net survival (NS) was estimated by the Pohar-Perme method.ResultsAmong 5812 patients diagnosed with having TETs, 58.9%, 38.1%, and 3.0% were diagnosed with having thymoma, thymic carcinoma, and thymic neuroendocrine tumor (NET), respectively. Age-standardized incidence rates were 0.50, 0.30, 0.18, and 0.02 per 100,000 for all TETs and the respective subtypes. There was an increase in incidence of all TETs (AAPC = 6.1%) and subtypes: thymoma (AAPC = 5.6%), thymic carcinoma (AAPC = 7.0%), and thymic NET (AAPC = 3.4%). Proportions of patients with thymoma, thymic carcinoma, and thymic NET were 58.9%, 38.1%, and 3.0%, respectively. For thymoma, the relative proportion of distant stage decreased (19.4% in 2005 to 8.8% in 2017) and low-grade WHO subtype (A, AB, B1) increased faster than high-grade WHO type (B2, B3) (AAPC = 19.8% versus 9.6%). For thymoma, the 5-year NS was 82.3%. This increased from 64.3% in 1999 to 2002 to 90.6% in 2013 to 2017. For thymic carcinoma, the 5-year NS was 46.2% and only slightly increased from 39.4% in 1999 to 2002 to 47.9% in 2013 to 2017.ConclusionsThis study indicates a high incidence of TET and its continuous increase in Korea. The proportion of thymic carcinoma was relatively higher than in the United States or Europe. Survival for thymoma improved during the study period, whereas this was not evident for thymic carcinoma or thymic NET.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
疯了半天完成签到,获得积分10
刚刚
王强完成签到,获得积分10
1秒前
1秒前
dong东包发布了新的文献求助10
2秒前
西瓜完成签到 ,获得积分10
2秒前
小张完成签到,获得积分10
3秒前
EVEN发布了新的文献求助30
4秒前
王冉冉发布了新的文献求助10
4秒前
4秒前
研无止境w发布了新的文献求助10
5秒前
7秒前
奶油泡fu完成签到 ,获得积分10
7秒前
dong东包完成签到,获得积分20
8秒前
8秒前
ED应助cccccc采纳,获得10
8秒前
shangziru发布了新的文献求助10
9秒前
漠之梦完成签到,获得积分20
10秒前
sc完成签到,获得积分10
10秒前
谦让的含海完成签到,获得积分10
10秒前
好运連連完成签到,获得积分10
11秒前
13秒前
liu完成签到,获得积分10
13秒前
飞翔的霸天哥应助Yuanchaoyi采纳,获得30
14秒前
香蕉觅云应助WJH采纳,获得10
15秒前
汉堡包应助研友_LOoomL采纳,获得10
15秒前
小二郎应助Felix采纳,获得10
15秒前
zaphkiel完成签到 ,获得积分10
16秒前
健壮的囧完成签到,获得积分10
17秒前
torch132完成签到,获得积分10
18秒前
桐桐应助阿景采纳,获得10
19秒前
19秒前
震动的平松完成签到 ,获得积分10
19秒前
Ting完成签到 ,获得积分10
20秒前
20秒前
Hello应助王冉冉采纳,获得30
21秒前
Ava应助Jarvi采纳,获得10
21秒前
22秒前
23秒前
24秒前
一枚研究僧完成签到,获得积分0
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048